AQST (Aquestive Therapeutics) Total Liabilities: $188.69 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AQST Aquestive Therapeutics Inc AQST
49 GF Score
Price $5.16
GF Value $2.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Aquestive Therapeutics Total Liabilities?

Aquestive Therapeutics AQST -1.15% 49 Total Liabilities is $188.69 Mil as of Jun. 2026. GuruFocus rates AQST with a GF Score™ of 49/100 and a GF Value™ of $2.37 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Aquestive Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 was $188.69 Mil.

Aquestive Therapeutics's quarterly Total Liabilities declined from Dec. 2025 ($194.09 Mil) to Mar. 2026 ($175.18 Mil) but then increased from Mar. 2026 ($175.18 Mil) to Jun. 2026 ($188.69 Mil).

Aquestive Therapeutics's annual Total Liabilities declined from Dec. 2023 ($163.91 Mil) to Dec. 2024 ($161.58 Mil) but then increased from Dec. 2024 ($161.58 Mil) to Dec. 2025 ($194.09 Mil).

Aquestive Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Aquestive Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquestive Therapeutics Total Liabilities Chart

Aquestive Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.13 175.62 163.91 161.58 194.09

Aquestive Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 166.29 167.67 194.09 175.18 188.69
AQST
49GF Score
Aquestive Therapeutics Inc AQST
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aquestive Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aquestive Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=47.608+(31.856+95.233
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+19.39+0+0)
=194.09

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=160.425--33.662
=194.09

Aquestive Therapeutics's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.478+(58.179+95.188
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+18.845+0+0)
=188.69

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=132.104--56.586
=188.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $188.69 Mil mean?
Aquestive Therapeutics (AQST) has a Total Liabilities of $188.69 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aquestive Therapeutics and its competitors.
Is Aquestive Therapeutics' Total Liabilities too high?
Aquestive Therapeutics' current Total Liabilities is $188.69 Mil. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' Total Liabilities compare to TLRY and EOLS?
Aquestive Therapeutics' Total Liabilities of $188.69 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Aquestive Therapeutics and its competitors. Aquestive Therapeutics's current Total Liabilities is $188.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current Total Liabilities is $188.69 Mil. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current Total Liabilities is $188.69 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aquestive Therapeutics (AQST) Overvalued in 2026?

Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued. The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37. GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.

Key valuation signals for AQST:

  • Total Liabilities: $188.69 Mil
  • GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aquestive Therapeutics Business Description

Address 30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score

Get the complete analysis for AQST

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.16
Price
$2.37
GF Value